Genotyping and macrolide resistance of Mycoplasma pneumoniae identified in children with community-acquired pneumonia in Medellín, Colombia

Copete, Angela Rocio; Aguilar, Yudy; Rueda, Zulma Vanessa; Vélez, Lázaro A.

doi:10.1016/j.ijid.2017.11.019

Cited by 12 publications

(11 citation statements)

References 45 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mycoplasma pneumoniae is an atypical bacterium that can cause severe respiratory tract infections . In addition, it is a significant cause leading to the hospitalization of children with community‐acquired pneumonia . The incidence of mycoplasma pneumonia in children is high, which accounts for 16%‐30% of community‐acquired pneumonia in children .…”

Section: What Is Known and Objectivementioning

confidence: 99%

“…The incidence of mycoplasma pneumonia in children is high, which accounts for 16%‐30% of community‐acquired pneumonia in children . It is generally mild, but it can be very serious, even involves extra pulmonary spread, such as central nervous system, mucosa and other organs, which seriously endangered the health of children . Due to the serious side effects of tetracycline and fluoroquinolones on children, macrolides have become first choice for the treatment of mycoplasma pneumonia in children .…”

Section: What Is Known and Objectivementioning

confidence: 99%

“…1,2 In addition, it is a significant cause leading to the hospitalization of children with communityacquired pneumonia. 3,4 The incidence of mycoplasma pneumonia in children is high, which accounts for 16%-30% of communityacquired pneumonia in children. [5][6][7][8] It is generally mild, but it can be very serious, even involves extra pulmonary spread, such as central nervous system, mucosa and other organs, which seriously endangered the health of children.…”

Section: What Is K Nown and Objec Tivementioning

confidence: 99%

See 2 more Smart Citations

Comparative efficacy of Chinese herbal injections combined with azithromycin for mycoplasma pneumonia in children: A Bayesian network meta‐analysis of randomized controlled trials

Duan

Wang

et al. 2019

J Clin Pharm Ther

View full text Add to dashboard Cite

What is known and objectiveAn increasing macrolide resistance leads to complex clinical treatment schemes in mycoplasma pneumonia in children. Chinese herbal injection (CHI) is widely used to treat it and may provide a new treatment regimen. This study was conducted to systematically evaluate the efficacy of CHIs combined with azithromycin for treating mycoplasma pneumonia in children by Bayesian network meta‐analysis.MethodsRandomized controlled trials (RCTs) of CHIs combined with azithromycin for mycoplasma pneumonia in children were searched in electronic databases and related references from initiation to 30 October 2018. Two researchers conducted data extraction and risk of bias assessment. WinBUGS software and STATA software were adopted to analyse the data.ResultsA total of 167 RCTs were included with 5 CHIs involving 16 144 patients. All CHIs combined with azithromycin had superior effects than azithromycin only among overall outcomes. Yanhuning injection combined with azithromycin ranked highest in four different outcomes and second in two based on surface under the cumulative ranking probabilities (SUCRA). Meanwhile, the results of MD and 95% CIs of concerned outcomes indicated that only Yanhuning injection combined with azithromycin had better response than other CHIs combined with azithromycin. Moreover, cluster analysis results revealed Reduning injection combined with azithromycin was associated with a positive effect on the three group outcomes. Similarly, it was found to be the top three ranking in all outcomes based on SUCRA.What is new and conclusionYanhuning injection combined with azithromycin and Reduning injection combined with azithromycin were found to be preferable treatments based on the data of this study.

show abstract

Section: What Is Known and Objectivementioning

confidence: 99%

Section: What Is Known and Objectivementioning

confidence: 99%

Section: What Is K Nown and Objec Tivementioning

confidence: 99%

See 1 more Smart Citation

Comparative efficacy of Chinese herbal injections combined with azithromycin for mycoplasma pneumonia in children: A Bayesian network meta‐analysis of randomized controlled trials

Duan

Wang

et al. 2019

J Clin Pharm Ther

View full text Add to dashboard Cite

show abstract

“…However, severe cases requiring hospitalization and even death may happen, particularly among aging or immunocompromised people. Up to 25% of M pneumoniae patients presented extrapulmonary manifestations including the central nervous system, mucous membrane, and cardiovascular system . Some complications, for example, neurological manifestations, cause grave outcomes.…”

Section: Introductionmentioning

confidence: 99%

“…Up to 25% of M pneumoniae patients presented extrapulmonary manifestations including the central nervous system, mucous membrane, and cardiovascular system. 20 Some complications, for example, neurological manifestations, cause grave outcomes. Antibiotic treatment significantly moderates the symptoms and signs even before the thorough elimination of the bacteria.…”

mentioning

confidence: 99%

Pooled analysis of nuclear acid sequence‐based amplification for rapid diagnosis of Mycoplasma pneumoniae infection

Huang

Yao

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Mycoplasma pneumoniae (M pneumoniae) is a common human etiology of respiratory infections. Nuclear acid sequence‐based amplification (NASBA) shows good value for the detection of M pneumoniae that surpasses PCR. However, the optimal detection technology still remains to be identified. The purpose of this meta‐analysis was to systematically evaluate the overall accuracy of NASBA for diagnosing M pneumoniae infections.MethodsThe databases PubMed, Cochrane Library, Google Scholar, CNKI, Wang Fang, and Baidu Scholar were comprehensively searched from their initiation date to December 2017 for NASBA in the diagnosis of M pneumoniae infection. Meta‐DiSc 1.4 statistical software was used to evaluate the sensitivity (SEN), specificity (SPE), negative likelihood ratio (−LR), positive likelihood ratio (+LR), diagnostic odds ratio (DOR), and summary receiver operating characteristic (SROC). RevMan 5.2 statistical software was used for quality evaluation of the included articles. Publication bias was evaluated by funnel plot.ResultsSix articles with high quality, including 10 studies, were finally included in this meta‐analysis. The combined statistics results for the diagnosis of M pneumoniae infection by NASBA were 0.77 (SEN, 95% CI: 0.71 to 0.82); 0.98 (SPE, 95% CI: 0.98 to 0.99); 0.22 (‐LR, 95% CI: 0.13 to 0.39); 50.38 (+ LR, 95% CI: 21.85 to 116.17); 292.72 (DOR, 95% CI: 95.02 to 901.75); and 0.9875 (the area under the curve of SROC).ConclusionNuclear acid sequence‐based amplification is a reliable technique to diagnose M pneumoniae infection. However, whether it can replace PCR and serology need to be further studied.

show abstract

Antibiotic-Resistant Community-Acquired Bacterial Pneumonia

2019

Infectious Disease Clinics of North America

View full text Add to dashboard Cite

Genotyping and macrolide resistance of Mycoplasma pneumoniae identified in children with community-acquired pneumonia in Medellín, Colombia

Abstract: A variant of type 2 of M. pneumoniae prevailed among children with CAP during the study period. No strains with mutations associated with macrolide resistance were found.

Cited by 12 publications

References 45 publications

Comparative efficacy of Chinese herbal injections combined with azithromycin for mycoplasma pneumonia in children: A Bayesian network meta‐analysis of randomized controlled trials

Comparative efficacy of Chinese herbal injections combined with azithromycin for mycoplasma pneumonia in children: A Bayesian network meta‐analysis of randomized controlled trials

Pooled analysis of nuclear acid sequence‐based amplification for rapid diagnosis of Mycoplasma pneumoniae infection

Antibiotic-Resistant Community-Acquired Bacterial Pneumonia

Contact Info

Product

Resources

About